CLDX Celldex Therapeudics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLDX Celldex Therapeudics

CLDX 24.75

-7.4%

Nov 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (6)	12/26/2018 2:25:34 PM
From: scaram(o)uche	Read Replies (1) of 105

CDX-3379 trial (combo with EGFR antagonist) in HNSCC......... clinicaltrials.gov (Open label phase II, primary completion date 12/19.) Trial design and summary of previous clinical results with 3379........ celldex.com Results, open label phase I "window of opportunity" study........ celldex.com Preclinical rationale for current trial........ celldex.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next